Next Article in Journal
Predictors of Immunotherapy-Induced Immune-Related Adverse Events
Previous Article in Journal
Paroxysmal Nocturnal Hemoglobinuria Testing in Patients with Myelodysplastic Syndrome in Clinical Practice—Frequency and Indications
error_outline You can access the new MDPI.com website here. Explore and share your feedback with us.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 5
10.3747/co.25.3945
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14

by
J.B. Auliac
1,*,
S. Bayle
2,
A. Vergnenegre
3,
H. Le Caer
4,
L. Falchero
5,
R. Gervais
6,
H. Doubre
7,
F. Vinas
8,
B. Marin
3 and
C. Chouaid
8
1
Service de Pneumologie et Oncologie Thoracique, Hôpital François-Quesnay, 2 boulevard de Sully, Mantes-la-Jolie 78200, France
2
Oncology Department, Institut d’Oncology, Saint-Priest-en-Jarez, France
3
Chest Department, chu de Limoges, Limoges, France
4
Chest Department, ch Saint Brieux, Saint Brieuc, France
5
Chest Department, ch Villefranche, Villefranche, France
6
Oncology Department, Centre Francois Baclesse, Caen, France
7
Chest Department, Hôpital Foch, Suresnes, France
8
Chest Department, chi Créteil, Créteil, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(5), 398-402; https://doi.org/10.3747/co.25.3945
Submission received: 2 July 2018 / Revised: 5 August 2018 / Accepted: 7 September 2018 / Published: 1 October 2018

Abstract

Background: Mutations in BRAF are rare oncogene mutations, found in 2% of non-small-cell lung cancers (NSCLCS). Little information is available about the management of patients with BRAF-mutated nsclc, except for those included in clinical trials. We undertook the present study to assess the clinical characteristics, management, and outcomes of those patients in a real-life setting. Methods: This retrospective multicentre observational study included all patients with BRAF-mutated nsclc diagnosed between January 2012 and December 2014. Results: Patients (n = 59) from 24 centres were included: 57.6% men; mean age: 64.5 ± 14.5 years; 82% with a performance status of 0–1 at diagnosis; smoking status: 40.3% current, 32.6% former; 93% with adenocarcinoma histology; 75% stage iv; 78% with V600E mutations; 2 with EGFR and 2 with ALK co-mutations. Of the stage iv patients, 79% received first-line therapy (14.2% anti-BRAF), and 48% received second-line treatment (23.8% anti-BRAF). Response rate and progression-free survival were, respectively, 51.7% and 8.7 months [95% confidence interval (CI): 6.4 months to 15.2 months] for first-line therapy and 35.3% and 4.1 months (95% CI: 2 months to 10.9 months) for second-line treatments. The 2-year overall survival was 58.5% (95% CI: 45.8% to 74.8%). Outcomes in patients with stage iv nsclc harbouring BRAF V600E mutations (n = 32) did not differ significantly from those of patients with other BRAF mutations. Conclusions: In this real-world analysis, most nsclc patients with a BRAF mutation were men and current or former smokers. Survival appears to be better in these BRAF-mutated patients than in nsclc patients without an oncogenic driver.
Keywords: lung adenocarcinoma; V600E; BRAF mutation; prognosis; management lung adenocarcinoma; V600E; BRAF mutation; prognosis; management

Share and Cite

MDPI and ACS Style

Auliac, J.B.; Bayle, S.; Vergnenegre, A.; Le Caer, H.; Falchero, L.; Gervais, R.; Doubre, H.; Vinas, F.; Marin, B.; Chouaid, C. Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14. Curr. Oncol. 2018, 25, 398-402. https://doi.org/10.3747/co.25.3945

AMA Style

Auliac JB, Bayle S, Vergnenegre A, Le Caer H, Falchero L, Gervais R, Doubre H, Vinas F, Marin B, Chouaid C. Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14. Current Oncology. 2018; 25(5):398-402. https://doi.org/10.3747/co.25.3945

Chicago/Turabian Style

Auliac, J.B., S. Bayle, A. Vergnenegre, H. Le Caer, L. Falchero, R. Gervais, H. Doubre, F. Vinas, B. Marin, and C. Chouaid. 2018. "Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14" Current Oncology 25, no. 5: 398-402. https://doi.org/10.3747/co.25.3945

APA Style

Auliac, J. B., Bayle, S., Vergnenegre, A., Le Caer, H., Falchero, L., Gervais, R., Doubre, H., Vinas, F., Marin, B., & Chouaid, C. (2018). Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14. Current Oncology, 25(5), 398-402. https://doi.org/10.3747/co.25.3945

Article Metrics

Back to TopTop